Hepatitis B Postexposure Prophylaxis in Preterm and Low-Birth-Weight Infants

Abstract

Objective Recommendations for immunoprophylaxis in low-birth-weight (LBW) infants born to hepatitis B surface antigen (HBsAg)-positive mothers vary. We successfully immunized an HBsAg-exposed infant (birth weight: 400 g) and performed a literature review on the outcome of postexposure immunoprophylaxis in HBsAg-exposed preterm and LBW infants.

Methods By use of PubMed we identified articles relevant to the topic. Studies were included if the intended vaccine schedule was completed and follow-up data were reported.

Results Antibody response was reported in 31 LBW infants (birth weight < 2,500 g) and 49 infants with gestational age of < 38 weeks. Low anti-HBs antibody levels (< 100 IU/L) were found in 9 (29%) of the 31 LBW infants. Overall, 2 of 20 (10%) preterm infants and 2 of 17 (12%) LBW were HBsAg-positive on follow-up. In one study, none of the 26 exposed very LBW infants became infected.

Conclusion Due to heterogeneity in immunization schedules, lack of information on transmission rates, and the small number of included subjects, no firm conclusions can be drawn regarding the optimal postexposure prophylaxis in LBW infants. We propose that active and passive immunization at birth should be completed by three further active doses (0–1–2–12 month schedule) until further prospective studies are available.

Keywords

immunization - HBsAg - preterm neonate - postexposure

• References

• 1 Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274 (15) 1201-1208
• 2 Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105 (2) 94-98
• 3 Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, , eds. Viral Hepatitis and Liver Disease. New York, NY: Grune & Stratton; 1984: 209-224
• 4 Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993; 253 (1337) 197-201
• 5 Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20 (4) 992-1000
• 6 Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34 (6) 1329-1339
• 7 Mast EE, Margolis HS, Fiore AE , et al; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54 (RR-16): 1-31
• 8 Pickering LK. 2003 Red Book: Report of the Committee on Infectious Diseases, American. 26 ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003
• 9 Robert Koch Institute. Epidemiologisches Bulletin 07/2012. Available at: http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2012/Ausgaben/30_12.pdf . Accessed December 18, 2014
• 10 Lau YL, Tam AY, Ng KW , et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121 (6) 962-965
• 11 Linder N, Handsher R, German B , et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed 2000; 83 (1) F24-F27
• 12 Losonsky GA, Wasserman SS, Stephens I , et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103 (2) E14
• 13 Patel DM, Butler J, Feldman S, Graves GR, Rhodes PG. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr 1997; 131 (4) 641-643
• 14 Sood A, Singh D, Mehta S, Midha V, Kumar R. Response to hepatitis B vaccine in preterm babies. Indian J Gastroenterol 2002; 21 (2) 52-54
• 15 Gołebiowska M, Kardas-Sobantka D, Chlebna-Sokół D, Sabanty W. Hepatitis B vaccination in preterm infants. Eur J Pediatr 1999; 158 (4) 293-297
• 16 van Steenbergen JE, Leentvaar-Kuijpers A, Baayen D , et al. Evaluation of the hepatitis B antenatal screening and neonatal immunization program in Amsterdam, 1993-1998. Vaccine 2001; 20 (1–2) 7-11
• 17 Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007; 166 (8) 813-818
• 18 Chen CY, Chen HL, Chou HC, Tsao PN, Hsieh WS, Chang MH. Weight-based policy of hepatitis B vaccination in very low birth weight infants in Taiwan: a retrospective cross-sectional study. PLoS ONE 2014; 9 (3) e92271
• 19 Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, Tachibana Yoshida CF, Sandoval de Souza CB. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine 2002; 20 (11-12) 1557-1562
• 20 Yates TA, Paranthaman K, Yu LM , et al. UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure. Arch Dis Child 2013; 98 (6) 429-433
• 21 West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14 (11) 1019-1027
• 22 Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective?. J Infect Dis 1999; 179 (2) 489-492